Catecholamine-sensitive adenylate cyclase in frontal cortex of primate brain

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Adenylate cyclase (AC) activity in the brain is crucial for signal transduction.
• Catecholamines like dopamine and norepinephrine are key neurotransmitters influencing brain function.
• Understanding receptor subtypes involved in AC regulation is essential for neuroscience research.

Purpose of the Study:

• To investigate the effects of various neurotransmitters and modulators on adenylate cyclase activity in monkey frontal cortex.
• To characterize the receptor subtypes involved in catecholamine-mediated AC stimulation.
• To explore the role of calcium ions (Ca2+) in modulating neurotransmitter-stimulated AC activity.

Main Methods:

• Measurement of adenylate cyclase (AC) activity in homogenates of monkey frontal cortex.
• Stimulation of AC using catecholamines (dopamine, norepinephrine, isoproterenol), apomorphine, clonidine, NaF, and GPP(NH)P.
• Assessment of the effects of varying calcium (Ca2+) concentrations on AC activity.
• Pharmacological characterization using receptor antagonists (fluphenazine, haloperidol, propranolol, phentolamine).

Main Results:

• Adenylate cyclase activity was stimulated by dopamine, norepinephrine, isoproterenol, apomorphine, clonidine, NaF, and GPP(NH)P.
• Calcium ions (Ca2+) modulated neurotransmitter-stimulated AC activity, with inhibition observed at higher concentrations.
• Distinct receptor systems were identified: a beta-receptor activated by isoproterenol and a novel dopamine/norepinephrine receptor, distinct from known dopamine receptors, activated by dopamine and norepinephrine.
• The novel dopamine/norepinephrine receptor showed unique characteristics, including stimulation by clonidine and sensitivity to specific antagonists.

Conclusions:

• At least two distinct receptor types modulate adenylate cyclase activity in the monkey frontal cortex.
• One receptor is a beta-receptor responsive to isoproterenol.
• A novel dopamine/norepinephrine receptor, distinct from classical dopamine receptors, is also involved, showing unique pharmacological properties.